Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
22 studies found for:    Lambert-Eaton Myasthenic Syndrome
Show Display Options
Download search resultsDownload the search results for:
Lambert-Eaton Myasthenic Syndrome (22 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Available Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
2 Completed A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate;   Drug: Placebo
3 No longer available Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 DAP
4 No longer available Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Condition: Lambert Eaton Myasthenic Syndrome (LEMS)
Intervention: Drug: 3,4-diaminopyridine
5 Unknown  Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Conditions: Lambert-Eaton Myasthenic Syndrome;   Eaton-Lambert Myasthenic Syndrome
Interventions: Drug: 3,4-DAP;   Drug: 3,4-DAP Taper to Placebo
6 Recruiting 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome
Interventions: Drug: 3,4-DIAMINOPYRIDINE;   Drug: 3,4-Diaminopyridine
7 Available Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP
8 Available 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS);   Congenital Myasthenia (CM)
Intervention: Drug: 3,4-diaminopyridine
9 Available Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome
Conditions: Congenital Myasthenic Syndrome;   Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4-Diaminopyridine
10 Completed Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4-diaminopyridine
11 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
12 Recruiting Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Condition: Lambert-Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate;   Drug: Placebo Oral Tablet
13 Available Treatment Use of 3,4-Diaminopyridine
Conditions: Lambert Eaton Myasthenic Syndrome (LEMS);   Myasthenic Syndromes, Congenital
Intervention: Drug: 3,4-diaminopyridine
14 Completed Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Condition: Congenital Myasthenic Syndrome
Intervention: Drug: Albuterol
15 Available Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome;   Downbeat Nystagmus
Intervention: Drug: Amifampridine Phosphate
16 Recruiting Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Condition: Myasthenic Syndromes, Congenital
Interventions: Drug: amifampridine phosphate;   Drug: Placebo
17 Enrolling by invitation Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
Condition: Muscle Weakness
Intervention: Drug: 3-4 Diaminopyridine
18 Completed Pregnancy Outcomes in Congenital Myasthenie Syndrome
Condition: Congenital Myasthenic Syndrome
Intervention:
19 Unknown  Ephedrine for the Treatment of Congenital Myasthenia
Condition: Myasthenic Syndromes, Congenital
Intervention: Drug: Ephedrine
20 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Congenital Muscular Dystrophy (Including Unspecified/Undiagnosed);   Dystroglycanopathy;   Congenital Fiber Type Disproportion;   Rigid Spine Muscular Dystrophy;   Congenital Myopathy (Including Unspecified/Undiagnosed);   Collagen VI CMD (Ullrich CMD, Intermediate, Bethlem Myopathy);   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   LAMA2-CMD/Merosin Deficient/MDC1A;   Walker-Warburg Syndrome;   Muscle-Eye-Brain Disease;   Fukuyama/Fukutin Related Muscular Dystrophy;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   LMNA-CMD/Lamin A/C/Laminopathy;   SEPN1-Related Myopathy;   Bethlem Myopathy;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Myopathy;   Reducing Body Myopathy;   Spheroid Body Myopathy;   LGMD1B (LMNA);   LGMD1E (DES);   LGMD2G (TCAP);   LGMD2H (TRIM32);   LGMD2I (FKRP);   LGMD2J (TTN);   LGMD2K (POMT1);   LGMD2M (FKTN);   LGMD2N (POMT2);   LGMD2O (POMGnT1);   LGMD2P (DAG1);   LGMD2Q (PLEC1);   LGMD2R (DES);   LGMD2S (TRAPPC11);   LGMD2T (GMPPB);   LGMD2U (ISPD);   LGMD2V (GAA);   Ullrich Congenital Muscular Dystrophy;   Titinopathy;   Choline Kinase B Receptor;   Emery-Dreifuss Muscular Dystrophy;   RYR1 Related Myopathy;   SYNE1/Nesprin Related Muscular Dystrophy;   Telethonin Related Muscular Dystrophy (TCAP/Titin-Cap);   Congenital Myasthenic Syndrome;   Escobar Syndrome;   Myofibrillar Myopathy;   Malignant Hyperthermia;   Alpha-Dystroglycan Related Muscular Dystrophy (DAG1, DPM1, DPM2, DPM3, FKRP, FKTN);   Alpha-Dystroglycan Related Muscular Dystrophy (GAA, ISPD, LARGE, POMT1, POMT2, POMGnT1);   Alpha-Dystroglycan Related Muscular Dystrophy (Unspecified/Undiagnosed/Other)
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.